Journal
FRONTIERS IN NEUROENDOCRINOLOGY
Volume 35, Issue 1, Pages 8-30Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yfrne.2013.08.001
Keywords
Adipokine; Adipose tissue; Aging; Alzheimer's disease; Biomarker; Insulin; Menopause; Metabolism; Mitochondria; Type 2 diabetes
Categories
Funding
- [R01AG032236]
- [P01AG026572]
- [R01AG033288]
- [F31AG044997]
- NATIONAL INSTITUTE ON AGING [F31AG044997, P01AG026572, P50AG005142, R01AG033288, R01AG032236] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Estrogen is a fundamental regulator of the metabolic system of the female brain and body. Within the brain, estrogen regulates glucose transport, aerobic glycolysis, and mitochondrial function to generate ATP. In the body, estrogen protects against adiposity, insulin resistance, and type II diabetes, and regulates energy intake and expenditure. During menopause, decline in circulating estrogen is coincident with decline in brain bioenergetics and shift towards a metabolically compromised phenotype. Compensatory bioenergetic adaptations, or lack thereof, to estrogen loss could determine risk of late-onset Alzheimer's disease. Estrogen coordinates brain and body metabolism, such that peripheral metabolic state can indicate bioenergetic status of the brain. By generating biomarker profiles that encompass peripheral metabolic changes occurring with menopause, individual risk profiles for decreased brain bioenergetics and cognitive decline can be created. Biomarker profiles could identify women at risk while also serving as indicators of efficacy of hormone therapy or other preventative interventions. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available